Table 1 (Abstract A19). Characteristics of the BECOME study population in Part 1
From: 13th European Headache Federation Congress 2019 - Abstracts
| Â | Part 1 (N=20,837) |
|---|---|
Prior prophylactic treatment failures | |
 No PPTF | 7880 (37.8) |
 ≥1 PPTF | 12,957 (62.2) |
  1 PPTF | 4137 (19.9) |
  2 PPTF | 3063 (14.7) |
  3 PPTF | 2244 (10.8) |
  ≥4 PPTF | 3513 (16.9) |
Monthly migraine days | |
 <4 MMD | 5358 (25.7) |
 ≥4 MMD | 15,479 (74.3) |
  4–7 MMD | 5796 (27.8) |
  8–14 MMD | 4916 (23.6) |
  ≥15 headache days, of which ≥8 were MMD | 4767 (22.9) |
First visit versus follow-up visit patients | |
 First visit | 5621 (27.0) |
 Follow-up visit | 15,216 (73.0) |
Medication overuse | |
 Any medication overuse | 3706 (17.8) |
 Any suspected medication overuse headache | 2464 (11.8) |
Outpatients versus inpatients | |
 Outpatient visits | 19,700 (94.5) |
 Inpatient visits | 650 (3.1) |
 Unclassified visits | 487 (2.3) |